Connect Biopharma (NASDAQ:CNTB) Given Buy Rating at HC Wainwright

Posted by Brenda Bartman on Oct 8th, 2026

Connect Biopharma (NASDAQ:CNTB – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.

CNTB has been the subject of a number of other research reports. BTIG Research lowered their price target on Connect Biopharma to $5.00 and set a “buy” rating for the company in a research report on Wednesday, September 30th. Weiss Ratings upgraded Connect Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 24th. Piper Sandler initiated coverage on Connect Biopharma in a research report on Friday, June 26th. They set an “overweight” rating and a $7.00 price objective for the company. Canaccord Genuity Group reduced their target price on shares of Connect Biopharma from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, September 16th. Finally, Wall Street Zen raised Connect Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Connect Biopharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.14.

Get Our Latest Stock Report on CNTB

Connect Biopharma Stock Down 6.8%

Shares of CNTB traded down $0.06 during mid-day trading on Thursday, reaching $0.88. The company’s stock had a trading volume of 1,210,032 shares, compared to its average volume of 1,441,842. Connect Biopharma has a 12-month low of $0.85 and a 12-month high of $3.82. The stock has a market cap of $55.46 million, a PE ratio of -0.74 and a beta of -0.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.37 and a quick ratio of 2.37. The company’s 50 day moving average is $1.83 and its 200 day moving average is $2.23.

Connect Biopharma (NASDAQ:CNTB – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.04. The firm had revenue of $2.75 million during the quarter, compared to analyst estimates of $0.74 million. Equities analysts anticipate that Connect Biopharma will post -1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Connect Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of CNTB. Bank of America Corp DE bought a new stake in shares of Connect Biopharma in the first quarter worth $41,000. Simplify Asset Management Inc. bought a new stake in Connect Biopharma during the first quarter valued at $135,000. Richmond Brothers Inc. acquired a new position in shares of Connect Biopharma in the 4th quarter valued at about $489,000. Knott David M Jr boosted its stake in Connect Biopharma by 93.9% during the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after acquiring an additional 187,835 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in Connect Biopharma during the 1st quarter worth approximately $1,945,000. Institutional investors own 58.72% of the company’s stock.

Connect Biopharma Company Profile

(Get Free Report)

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.